TP53 is a critical tumor-suppressor gene that is mutated in more than half of all human
cancers. Mutations in TP53 not only impair its antitumor activity, but also confer mutant p53 …

Hypoxia, a hallmark of solid tumors, determines the selection of invasive and aggressive
malignant clones displaying resistance to radiotherapy, conventional chemotherapy or …

The evolutionary processes that underlie the marked sensitivity of small cell lung cancer
(SCLC) to chemotherapy and rapid relapse are unknown,–. Here we determined tumour …

Somatic mutations in p53, which inactivate the tumour-suppressor function of p53 and often
confer oncogenic gain-of-function properties, are very common in cancer,. Here we studied …

Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced
ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor …

Overcoming multidrug resistance (MDR) is one of the major challenges in cancer therapy. In
this respect, Schiff base-related compounds (bearing a R 1 R 2 Cdouble bondNR 3 bond) …

Selenium is an essential trace element that is crucial for cellular antioxidant defense against
reactive oxygen species (ROS). Recently, many selenium-containing compounds have …

Cancer is a leading cause of death worldwide. Targeted therapies aimed at key oncogenic
driver mutations in combination with chemotherapy and radiotherapy as well as …

The cytotoxic anti-cancer drugs cisplatin, paclitaxel, doxorubicin, 5-fluorouracil (5-FU), as
well as targeted drugs including imatinib, erlotinib, and nivolumab, play key roles in clinical …

Despite the development of targeted therapy, drug resistance remains a primary hindrance
to curative treatment of various cancers. Among several novel approaches to overcome drug …